Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis

Table 1 Characteristics of included trials

Trials	Sample size (n)		Mean age (yr)		Regimen (mg/d)		Duration(wk)	Observationtime (wk)	Outcome parameters	HBV DNA undetectability (copy/mL)
	LDT	ETV	LDT	ETV	LDT	ETV
Zhao et al[12]	36	36	34.30		600	0.5	48	24, 48	ABDE	-
Zhu et al[13]	30	30	28.00 ± 9.10	31.80 ± 7.10	600	0.5	24	12, 24	ABCDE	1000
Zhou et al[14]	52	63	46.30 ± 9.00		600	0.5	48	12, 24, 36, 48	ACD	-
Xu et al[15]	30	30	32.70 ± 10.60	33.60 ± 8.80	600	0.5	24	12, 24, 48	ABCDF	1000
Ye et al[16]	46	46	32.20		600	0.5	48	12, 24, 48	ABCDE	100
Zhang et al[17]	75	65	31.93 ± 7.96		600	0.5	72	8 ,12, 24, 52, 72	ABDEF	500
Liu[18]	20	20	33.50		600	0.5	48	4, 12, 24, 48	ABCDF	1000
Zhao et al[19]	42	39	33.56 ± 10.25		600	0.5	60	8, 12, 24, 48, 60	ABD	1000
Shi et al[20]	40	40	30.50 ± 7.11	31.50 ± 7.95	600	0.5	24	12, 24	ABCD	500
Yu et al[21]	92	85			600	0.5	48	4, 8, 12, 24, 48	ACD	500
Huang et al[22]	90	90	28.80 ± 9.80		600	0.5	52	52	ABCDE	500
Ding et al[23]	30	30	37.20 ± 7.96	36.10 ± 7.12	600	0.5	48	4, 8, 12, 24, 36, 48	ABCDEF	1000
Zheng et al[24]	65	66	31.60 ± 8.70	33.50 ± 9.10	600	0.5	24	12, 24	AFCDF	500

A: Hepatitis B virus DNA undetectability; B: Alanine aminotransferase normalization; C: Hepatitis B e antigen loss; D: Hepatitis B e antigen seroconversion; E: Drug-resistance; F: Increased creatine kinase. LDT: Telbivudine; ETV: Entecavir; HBV: Hepatitis B virus.

Table 2 Sensitivity analysis

Index	Total HBeAg loss
	OR (95% CI)	P vaule
Excluding the minimum sample size trials[18]	1.64 (1.31, 2.05)	< 0.00010
Using random-effect model	1.68 (1.35, 2.09)	< 0.00001
Using fixed-effect model	1.69 (1.46, 1.97)	< 0.00001

OR: Odds ratio; HBeAg: Hepatitis B e antigen.